<DOC>
	<DOC>NCT00588731</DOC>
	<brief_summary>This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.</brief_summary>
	<brief_title>Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Cannabinoid Receptor Antagonists</mesh_term>
	<criteria>Schizophrenia or Schizoaffective disorder (DSMIV SCIDconfirmed), Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>